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Summary Statement: Dystrophin-deficient C. elegans have measurably weak muscle 
strength and mitochondrial dysfunction, and they respond to drug treatments standard in 
treating human Duchenne muscular dystrophy 
 
Abstract 
 Muscle strength is a key clinical parameter used to monitor the progression of human 
muscular dystrophies including Duchenne and Becker muscular dystrophies. Although 
Caenorhabditis elegans is an established genetic model for studying mechanisms and 
treatments of muscular dystrophies, analogous strength-based measurements in this disease 
model are lacking.  Here we describe the first demonstration of the direct measurement of 
muscular strength in dystrophin-deficient C. elegans mutants using a micropillar-based force 
measurement system called NemaFlex. We show that dys-1(eg33) mutants, but not dys-
1(cx18) mutants, are significantly weaker than their wild-type counterparts in early 
adulthood, cannot thrash in liquid at wild-type rates, and display mitochondrial network 
fragmentation in the body wall muscles as well as abnormally high baseline mitochondrial 
respiration. Furthermore, treatment with prednisone, the standard treatment for muscular 
dystrophy in humans, and melatonin both improve muscular strength, thrashing rate, and 
mitochondrial network integrity in dys-1(eg33), and prednisone treatment also returns 
baseline respiration to normal levels. Thus, our results demonstrate that the dys-1(eg33) strain 
is more clinically relevant than dys-1(cx18) for muscular dystrophy studies in C. elegans. 
This finding in combination with the novel NemaFlex platform can be used as an efficient 
workflow for identifying candidate compounds that can improve strength in the C. elegans 
muscular dystrophy model. Our study also lays the foundation for further probing of the 
mechanism of muscle function loss in dystrophin-deficient C. elegans, leading to knowledge 
translatable to human muscular dystrophy. 
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Introduction 
 
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are 
muscular wasting disorders that affect both skeletal and cardiac muscle and result from 
mutations in the dystrophin gene (Le Rumeur, 2015). Dystrophin is a protein encoded from 
the longest human gene, which is over 2.3 million base pairs and has complex interactions 
with muscle contraction and muscle cell membrane stability (Den Dunnen et al., 1989, Blake 
et al., 2002). DMD results from null mutations in the gene, while BMD is a less severe form 
that is typically caused by a mutation resulting in a partially functional dystrophin protein (Le 
Rumeur, 2015). The prevalence of these diseases is more than 1 in 4000 male births, 
expressing as an x-linked disorder. Prognosis is poor (Moser, 1984) and the only standard 
approved treatment in the U.S. for symptoms of DMD is the corticosteroid prednisone, which 
typically has the effect of extending ambulation by a couple years (DeSilva et al., 1987). 
Although the increase in ambulatory period is a favorable outcome of treatment, chronic 
prednisone use typically results in a cushingoid appearance and other unfavorable side effects 
(Mendell et al., 1989, Malik et al., 2012). Thus the prognosis and options for MD treatment 
are rather limited. 
 
To monitor progression of the disease or to test for efficacy of treatments, various 
diagnostic tools have been studied to monitor the deterioration of muscle in DMD patients. 
One diagnostic tool used is an electronic strain gauge that measures isometric muscle 
strength; this tool can discern DMD patients from the control in all muscle groups tested, 
with the most drastic differences occurring in the knee extensors, where DMD patients have 
less than a tenth of the strength of the control group (Brussock et al., 1992). Quantitative 
muscle testing (QMT), a method that is more sensitive to small changes in muscle strength, is 
also being implemented in young patients with DMD to monitor muscle strength across age. 
QMT is able to detect isometric and isokinetic losses in strength before the end of the first 
decade of life (Lerario et al., 2012). These are just two examples of a larger research effort to 
obtain more reliable measures of muscle strength, as muscle strength is regarded as a key 
clinical parameter of interest in tracking DMD disease progression. Over the past half 
century, research efforts surrounding muscular dystrophy have grown significantly, but we 
still have much to learn about this debilitating disease. 
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While there have been extensive research efforts to better understand the mechanisms 
of and treatments for muscular dystrophy in vertebrate model organisms such as rodents and 
canines, these systems are limited in their throughput, can be cost prohibitive, and also have 
some ethical issues (McGreevy et al., 2015). This has led researchers to utilize C. elegans to 
study muscular dystrophy over the past couple of decades (Ségalat, 2006, Chamberlain and 
Benian, 2000). C. elegans is a premier model organism for studying a number of biological 
processes and human diseases, with an estimated 40% of human disease genes having an 
orthologue in C. elegans (Culetto and Sattelle, 2000). The ability to translate results from C. 
elegans to humans comes in part from conserved major biological pathways between the two 
organisms and a fully sequenced nematode genome (The C. elegans Sequencing Consortium, 
1998). C. elegans also has musculature strikingly similar to humans, with the presence of 
dense bodies (analogous to z-disks) and m-lines (Gieseler et al., 2016). A number of muscle 
proteins in C. elegans resemble human proteins in their function, making C. elegans an 
excellent model for studying muscle ailments such as sarcopenia or muscular dystrophy 
(Ségalat, 2002). In addition to these factors, C. elegans also has a short lifespan of only 3 
weeks, produces a new generation every 3.5 days, and is low-maintenance with cultures 
grown on agar medium and an E. coli diet.  
 
Several mutant strains of C. elegans have been generated for investigating 
mechanistic details of and pharmacological treatments for dystrophin deficiency. About two 
decades ago, Bessou et al. reported a gene in C. elegans that they called dys-1 (Bessou et al., 
1998). Dys-1 encodes a protein resembling the human dystrophin protein not properly 
transcribed in DMD and BMD. These C. elegans dys-1 mutants are hyperactive, have 
exaggerated head bending, hypercontract their bodies during backwards movements, and are 
hypersensitive to the acetylcholinesterase inhibitor aldicarb. However, the animals do not 
show visible defects in their musculature, which the authors attribute to the short timescale of 
the nematode’s life (Bessou et al., 1998). To address the need for a health measure related 
directly to the musculature in dys-1 mutants, Gieseler et al. generated a sensitized dys-1 
mutant containing an additional mutation in the hlh-1 gene, which is a homolog for the 
mammalian MyoD gene (Gieseler et al., 2000). The presence of the hlh-1 mutation in a dys-1 
mutant background results in significant muscle cell degeneration that is not present in 
mutants with either the hlh-1 or dys-1 mutation alone (Gieseler et al., 2000). This type of 
double mutation was modeled after a similar MyoD mutation studied in conjunction with the 
mdx mouse model, which was generated in part to create a system that recapitulated the 
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pathophysiology of DMD in humans (Megeney et al., 1996). Using this dys-1;hlh-1 model of 
muscular dystrophy, pharmacological compounds like prednisone and serotonin have been 
shown to be effective in reducing muscle cell degeneration. These two treatments came as 
hits out of large-scale screens where hundreds of other compounds were deemed ineffective 
(Gaud et al., 2004, Carre-Pierrat et al., 2006). 
 
While these studies have helped to establish C. elegans as a model organism for 
muscular dystrophy and pharmacological treatments for the disease, two main criticisms 
arise. First, it is unknown whether results from the dys-1;hlh-1 double mutant models can be 
translated to muscular dystrophy in humans, especially given that the mechanism of these 
enhanced muscular degeneration effects in C. elegans is not fully understood. Second, 
although several assays for assessing health of dys-1 mutants have been proposed, most fail 
to directly score animals for muscle function and instead look at indirect physiological 
parameters such a locomotion speed or subcellular markers such as muscle cell damage. 
Recently Beron et al. scored the percentage of worms that can travel a set distance in a certain 
amount of time when placed in a 3D burrowing environment. Animals are stimulated by 
chemotaxis to burrow down the length of a plastic pipette filled with agar; dys-1(cx18) and 
dys-1(eg33) are both highly deficient in burrowing ability compared to the wild-type control 
(Beron et al., 2015). This work indicates that the dys-1 mutants may be unable to burrow 
correctly due to defects in muscular strength.  
 
Although these assays are undoubtedly valuable, the ability to directly evaluate 
muscle function would offer a more meaningful dimension to assessing the health of 
dystrophin mutants under treatments given that strength is a clinical measure used to assess 
progression of DMD in humans. Previously our group established a novel technique and 
workflow for reliably measuring the muscle strength of C. elegans, independent of their 
behavior. This platform, NemaFlex, consists of a microfluidic device containing deformable 
pillars that the worm deflects as it crawls in the chamber. Nematode strength is scored from 
the maximal pillar deflections via a sophisticated image processing software (Rahman et al., 
2018). To establish strength as a phenotype of interest for assessing health in dys-1 mutants, 
we used NemaFlex for studying two different dys-1 strains, dys-1(cx18) and dys-1(eg33), 
alongside the wild-type animal. We then show that our platform can detect 
pharmacologically-induced improvements by assessing the effects that melatonin and 
prednisone, compounds known to improve muscle health, have on the muscular strength of 
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the same animals. We also evaluated whether the thrashing data and mitochondrial integrity 
for control and treatment groups agreed with the strength data. Finally, we show that 
mitochondrial network integrity and mitochondrial function are impaired in dys-1(eg33), and 
treatment with prednisone repairs these defects. This work addresses the current gap in the 
ability to obtain strength measures in DMD model mutants, which will ultimately lead to a 
better understanding of muscular dystrophy. Additionally, our results indicate that dys-
1(eg33) has a more pronounced and clinically relevant phenotype than what has been 
reported previously for dys-1 mutants. We can detect our clinically relevant phenotype in the 
absence of the hlh-1 sensitizing mutation, which better establishes C. elegans dys-1 mutants 
as a useful model for studying muscular dystrophy. 
 
Results 
 
dys-1(eg33), but not dys-1(cx18) worms, are weaker than wild-type 
 
While both dys-1 mutants have previously been shown to have declined locomotory 
capability and decreased lifespan compared to the wild-type animal (Oh and Kim, 2013), 
direct measures of muscle functionality in clinically relevant models do not exist. We 
addressed this limitation by utilizing our microfluidic platform called NemaFlex that enables 
measurement of muscular strength of C. elegans (Rahman et al., 2018). Using two previously 
studied dystrophin-deficient mutants, dys-1(eg33) and dys-1(cx18), we investigated whether 
these animals were weaker than the wild-type animal (N2). The alleles eg33 and cx18 are 
nonsense mutations predicted to encode truncated forms of DYS-1 at AA3287 and AA2721, 
respectively (Oh and Kim, 2013). Animal strength of WT, dys-1(cx18), and dys-1(eg33) was 
measured on Days 1, 3, and 5 of adulthood (Fig. 1A). While neither mutant strength value 
was significantly different than wild type on the first day of adulthood, dys-1(eg33) animal 
strength essentially plateaued while wild type and dys-1(cx18) continued to grow stronger at 
the later time points, potentially partially attributable to the increase in animal diameter in 
early adulthood. This led to dys-1(eg33) being significantly weaker than the wild-type control 
on Days 3 and 5, thus establishing the dys-1(eg33) strain as a model exhibiting muscular 
weakness with age, which is similar to the phenotype displayed in muscular dystrophy. It is 
important to note that animal diameter, but not length, strongly affects muscle strength of C. 
elegans, as we previously reported that strength tends to increase with body diameter 
(Rahman et al., 2018). Therefore we checked whether muscle strength deficiencies in dys-
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1(eg33) were attributable to differences in their diameters compared to wild-type animals 
(Fig. 1B). At no time point are dys-1(eg33) animals significantly thinner than wild type, thus 
indicating that their strength defect is not a size-based effect, and we are truly measuring 
strength deficiencies resulting from defects in muscle function.  
 
All treatments improve dys-1(eg33) strength, some to wild-type levels 
 
Since NemaFlex can detect muscular weakness in dys-1(eg33), a meaningful next step 
is to test whether compounds known to improve muscle health can also improve muscle 
strength in muscular dystrophy models. Melatonin and prednisone were selected for 
validation of NemaFlex as a platform for screening compounds for treatment of dystrophin 
deficiency in C. elegans. Melatonin is thought to be potentially useful in treating muscle 
degradation with age (Coto-Montes et al., 2016) and has also been used to treat muscular 
dystrophy patients (Chahbouni et al., 2010), while prednisone is the standard treatment for 
muscular dystrophy patients (Malik et al., 2012) and has also been shown to decrease the 
number of abnormal muscle cells in the dys-1; hlh-1 double mutant strain of C. elegans 
(Gaud et al., 2004). The mechanism behind prednisone’s improvement in muscle function is 
still up for debate, but the efficacy of prednisone previously shown in C. elegans provides 
evidence that corticosteroids may treat the muscle in ways other than reducing inflammation, 
given that C. elegans does not have an inflammatory pathway (Gaud et al., 2004). 
In general, we find that wild-type and dys-1(cx18) animals treated both during 
development only and continuing through adulthood were not significantly different from 
their control counterpart at all three time points (Fig. 2A,B). In contrast, beginning on Day 3 
of adulthood when dys-1(eg33) animals are significantly weaker than wild type, all four 
treatments improve muscular strength compared to the untreated dys-1(eg33) animals (Fig. 
2C).  Moreover it is important to note that worm diameters are minimally affected under 
treatments for wild type (Fig 2D), dys-1(cx18) (Fig. 2E), and dys-1(eg33) (Fig. 2F). Of 
particular importance is that on Days 3 and 5, when dys-1(eg33) has significant 
improvements in muscle strength, there are no changes in worm diameter under any treatment 
condition. Thus, improvements in animal strength are not due to changes in animal size, but 
rather due to improvements in muscle function. Under some treatments, differences between 
the wild-type control and treated dys-1(eg33) are indiscernible. Several treatments improve 
animal strength by over 50% and get within 10% of the wild-type control strength value. As 
anticipated, these treatments improve muscle functionality in the muscular dystrophy model 
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in a manner that can be detected by NemaFlex. This establishes our technology as a useful 
platform for future studies screening novel compounds on dys-1(eg33) to select potential 
therapies for muscular dystrophy. Because dys-1(eg33) is showing such a distinct phenotype 
from dys-1(cx18), which has been studied more thoroughly, we were interested in 
investigating the difference between these two strains and why dys-1(eg33) seems to have 
more clinical relevancy.  
 
Functional defects are apparent in swimming-based movement assays 
 
A standard assay for detecting locomotion defects is to record a worm’s thrashing 
frequency when placed in a liquid environment, and this assay has been used previously to 
look at dystrophin-deficient worms, although not in both the dys-1 strains we have used in 
this study (Hueston and Suprenant, 2009). We were curious to compare the outputs of an 
indirect measure of muscle function, thrashing, with our more direct measure, the strength 
measurement. Interestingly, while muscle strength of dys-1(cx18) was not significantly less 
than the wild-type animal, its thrashing rate is significantly less than that of wild type. dys-
1(eg33) also shows a lower thrashing rate, consistent with its lower strength (Fig. 3A). On 
Day 1 of adulthood, dys-1(eg33) is significantly worse at thrashing than dys-1(cx18), 
although on later days the two strains cannot be differentiated. When all strains were treated 
with life-long melatonin or prednisone, there were some noticeable changes in thrashing rate, 
although not the same as the changes in muscle strength in all cases. Wild-type animals had 
varying responses to the drugs, with the drugs not having a consistent effect on the worms 
across the time points studied (Fig. 3B,C). However, both treatments give a minor 
improvement in dys-1(cx18) (Fig. 3C), and in dys-1(eg33) both treatments offer a significant 
improvement in thrashing rate at all time points (Fig. 3D). This result matches well with the 
strength data, where all drug treatments improve muscle strength in dys-1(eg33). The 
thrashing assay thus helps to further implement dys-1(eg33) as a more clinically relevant 
model where measures from two unique modes of locomotion show improvement when 
treated with compounds known to improve muscle health, particularly in patients with 
muscular dystrophy. 
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 Dys-1(eg33) mutants have a more severe phenotype than dys-1(cx18) 
 
Given that strength and thrashing ability are not compromised to the same extent in dys-
1(cx18) as in dys-1(eg33), we wanted to further investigate the differences between the two 
strains. In reviewing the published literature on dys-1(cx18) we found that Hueston and 
Suprenant (2009) had previously observed worse locomotion at 25˚C than at 20˚C, which 
would be consistent with cx18 being a temperature sensitive allele. We confirmed that dys-
1(cx18), but not dys-1(eg33), displays temperature sensitivity in the extent of thrashing ability 
(Fig 4A). We next examined if differences between dys-1(cx18) and dys-1(eg33) extended to 
differences in excitation-contraction coupling. Both dys-1(cx18) and dys-1(eg33) display 
resistance to levamisole-induced paralysis, indicative of defects in post-synaptic excitation-
contraction coupling, with dys-1(eg33) displaying more pronounced levamisole resistance 
(Fig 4B). Similar to the thrashing ability, dys-1(cx18) displayed temperature sensitivity to the 
effects of levamisole (Fig 4C). These results confirm the past observation that dys-1(cx18) is 
a temperature sensitive allele of dys-1 and confirm that muscle responsiveness to a 
depolarizing signal is more compromised in dys-1(eg33).  
 
Dystrophin mutants display normal sarcomere structure  
 
We visualized the sarcomere structure of dys-1(cx18) and dys-1(eg33) worms to 
determine whether defects in muscle structure account for the reduced strength and motility 
in the dys-1 worms. Similar to previous studies (Gieseler et al., 2000), we also detect no 
major differences in sarcomere structure in the dys-1(eg33) and dys-1(cx18) compared to 
wild-type worms, by either phalloidin staining (Fig. 5A) or visualization of myosin tagged 
GFP (Fig. 5B). These findings suggest that the reductions in strength are not attributed to 
changes in muscle architecture in the dys-1 strains and are perhaps a result of different 
mechanism(s).  
 
Mitochondrial fragmentation is a phenotype of dystrophin mutants 
 
To determine possible underlying mechanisms behind the loss of muscle strength in 
dystrophin mutants, we looked at the integrity of the mitochondrial network of dys-1(cx18) 
and dys-1(eg33) animals that had been crossed with the CB5600 strain, which expresses GFP 
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in the mitochondria and nuclei of the body wall muscles. Recently, Scholtes et al. (2018) 
reported mitochondrial fragmentation as a phenotype of their sensitized muscular dystrophy 
strain, dys-1;hlh-1. Here we report that mitochondrial network integrity is also compromised 
in dys-1(cx18) and dys-1(eg33) compared to wild-type animals of the same age, with the 
defect in dys-1(eg33) being more severe (Fig. 5C-E). Both prednisone and melatonin 
improve the mitochondrial integrity of dys-1(eg33) animals. This offers a potential 
mechanistic explanation for why muscle function appears to be more severely affected in dys-
1(eg33) than dys-1(cx18), as well as further evidence that prednisone and melatonin are 
directly improving muscle health in dys-1(eg33). 
 
Mitochondrial function is affected in dys-1(eg33) mutants 
 
 Having identified that mitochondrial network structure appears disrupted in dys-1 
mutants and that this is improved with prednisone treatment, we were curious if 
mitochondrial function was similarly affected. We first used mitochondrial dyes to assess 
mitochondrial membrane potential. JC-10 is a dye that collects in the mitochondria based 
upon on membrane potential and also exits as mitochondrial membrane potential changes 
over time, as previously shown in another C. elegans mutant (Gaffney et al., 2015). 
Compared to wild-type animals, dys-1(cx18) has a somewhat reduced mitochondrial 
membrane potential, while dys-1(eg33) is more severely affected (Fig. 6A). To confirm these 
defects in mitochondrial membrane potential we used a second dye, MitoTracker Red, which 
collects in the mitochondria based upon membrane potential, but unlike JC-10, does not exit 
the mitochondria once inside (Gaffney et al., 2014). The MitoTracker accumulation matched 
that of JC-10 (Fig. 6A), demonstrating that the impaired membrane potential in the JC-10 
dyed worms was not an artifact of loss of membrane potential during the staining procedure. 
Interestingly, with both dyes, prednisone does not improve the defect in membrane potential 
in dys-1(eg33), indicating that improvements that we see in strength and thrashing rate in dys-
1(eg33) under prednisone treatment can be attributed to a different mechanism. 
In order to quantify the defect in mitochondrial function in dys-1(eg33) mutants, we 
assessed oxygen consumption rates (OCR). While dys-1(cx18) have normal OCR compared 
to wild type, dys-1(eg33) have abnormally high baseline respiration (Fig. 6B). Treatment 
with the uncoupling agent FCCP (Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) 
revealed that unlike wild-type and dys-1(cx18), dys-1(eg33) had no statistically significantly 
detectable, spare respiratory capacity (Fig. 6B). No statistically significant differences in non-
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mitochondrial respiration, as assessed by treatment with sodium azide, were found between 
the strains. Thus, the lack of spare respiratory capacity in dys-1(eg33) is likely a key driver of 
the increased severity of muscle defects in dys-1(eg33) vs. dys-1(cx18).  
Given that prednisone treatment improves muscle strength, thrashing rate, and 
mitochondrial network integrity in dys-1(eg33), we were interested in determining if 
prednisone could also normalize the aberrantly high basal OCR. Indeed, treating dys-1(eg33) 
with prednisone returned basal OCR to wild-type levels (Fig. 6C). These results combined 
with the lack of major effect of prednisone on mitochondrial membrane potential (Fig. 6A) 
suggest that prednisone has a predominant effect on mitochondrial respiratory function rather 
than restoring membrane potential. This is interesting as Brouilly et al. (2015) recently 
showed that prednisone improves muscle membrane structure, including the mitochondria, in 
dys-1;hlh-1.  
 
Discussion 
 
Strength as a novel phenotype for C. elegans DMD studies 
 
In the present study we demonstrate the ability to measure the strength of C. elegans 
dys-1 mutants and detect functional improvements in muscle strength in dys-1(eg33) after 
treatment with compounds known to improve muscle health. Previously there was not a 
means to directly measure the strength of C. elegans, but recently our group has established a 
consistent and reliable strength measurement routine using our microfluidic NemaFlex device 
(Rahman et al., 2018). This has allowed us to demonstrate for the first time that strength 
deficiency is a phenotype of the dys-1(eg33) strain, which further represents C. elegans as a 
useful model for replicating some of the pathophysiologies of human diseases in nematodes. 
For high throughput drug screens with dystrophin-deficient C. elegans, it may not be 
feasible to measure a large quantity of parameters to quantify nematode health. We show here 
that the thrash assay detects deficiencies in both dys-1 mutants and improvements under 
treatment with compounds. However, a decrease in thrashing rate does not necessarily 
correlate with a loss of muscle strength. For example, wild-type animals have lower thrashing 
rates on days 3 and 5 than on day 1, although there is not a strength decline at this same time 
point. Therefore thrashing rate and muscle strength measures do not necessarily report on the 
same aspect of worm physiology. For the purpose of high throughput drug screens, an 
automated version of the thrashing assay would be a quicker way of determining hits 
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(Buckingham et al., 2014); we propose that our NemaFlex system would be useful in 
validating whether these drugs also improve the more clinically relevant measure of muscle 
strength. Further automation of our NemaFlex imaging and post-imaging analysis protocol 
could help make NemaFlex more reasonable as a first-step screening assay; however, under 
the current protocol throughput is somewhat limited and would thus be more appropriate as 
an assay to validate hits that come out of a thrashing-based drug screen or other high 
throughput screening method. 
 Therefore, we propose that a direct measure of muscle function is perhaps the most 
valuable single measure to extract from drug screens. We recognize the value in assessing 
other physiological abilities, as dys-1(eg33) are also deficient in thrashing and burrowing. 
Advantages of our system over the previously reported burrowing assay (Beron et al., 2015) 
include the ability to culture the nematode over its whole life while maintaining individual 
worm identity, temporal control of the contents of the fluidic environment, no requirement of 
a stimulus for observation of the desired phenotype, and a transparent platform for clear 
imaging.  
Previous studies with dystrophin-deficient C. elegans have also looked at non-
physiological measures that aim to assess the integrity of the muscle rather than the function. 
If muscle strength is improved under a certain drug treatment, previously described assays 
looking at non-physiological measures should then be used to further assess the efficacy of 
the treatment. Our transgenic dys-1 strains expressing GFP in mitochondria of the body wall 
muscle that we report here are perfectly suited for this purpose, although other methods have 
previously been reported as well. Beron et al. (2015) looked at muscle degeneration in 
burrowing animals by tagging muscle cell nuclei and mitochondria with GFP, and others 
have looked at body wall muscle integrity after staining (Gieseler et al., 2000, Mariol and 
Ségalat, 2001). Looking at muscle cell integrity under a certain drug treatment could thus 
entail using the dys-1;hlh-1 mutant or allowing worms to burrow in the presence of the drug 
of interest to hasten muscle damage in one of the single mutation dys-1 strains.  
 
Difference in muscle strength and other phenotypes between dys-1(eg33) and dys-1(cx18) 
 
The inability of NemaFlex to detect muscular defects in dys-1(cx18) in a crawling 
environment is not surprising given that adult worms similarly aged to the ones studied here 
have no abnormal muscle cells and are indiscernible from wild-type animals based on this 
parameter (Gieseler et al., 2002). Additionally, the mitochondrial fragmentation is not as 
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severe in dys-1(cx18) as in dys-1(eg33). However, the question still remains on what the key 
differences are between dys-1(eg33) and dys-1(cx18) that lead to these drastic differences in 
muscle functionality, especially given that both animals are deficient in thrashing (our results 
here) and burrowing (Beron et al., 2015). Crawling, swimming, and burrowing are 
kinematically distinct from one another and offer unique challenges for the worm; observing 
different phenotypes among these environments may result from this distinction. It is likely 
that the burrowing assay challenges the muscles in a way not done in NemaFlex. Burrowing 
relies on the head muscles, while the NemaFlex analysis selects for the maximum force 
exertion, typically coming from body wall muscles. Therefore if head muscles were weaker, 
our system would not detect this under the current workflow. We also see that in the 
swimming worms, where both dys-1(cx18) and dys-1(eg33) are slower thrashers, dys-1(cx18) 
does not respond quite as strongly to the drug treatments. 
Further assessment with these three unique functional readouts along with future 
efforts targeting mechanistic questions may help answer why dys-1(eg33) shows an impaired 
phenotype and dys-1(cx18) does not. Previous work with C. elegans has identified defects in 
calcium signaling and acetylcholine sensitivity as pathophysiologies associated with 
dystrophin deficiency, so it is possible that these defects are more severe in dys-1(eg33) than 
dys-1(cx18) (Mariol and Ségalat, 2001, Zhan et al., 2014, Bessou et al., 1998, Giugia et al., 
1999). However, both strains are also reported as having null mutations, indicating that 
neither strain should produce even a partially functional dystrophin product. It thus remains 
unclear why the worms exhibit some distinct phenotypes from one another, but our data 
reported in this paper support the notion that there are fundamental differences between dys-
1(eg33) and dys-1(cx18). The more severe phenotype of dys-1(eg33) in its levamisole 
resistance and basal oxygen consumption rate, as well as the temperature-sensitive nature of 
dys-1(cx18) offer further perspective on why these strains differ from one another in their 
physiologies. 
Oh and Kim (2013) previously showed that dys-1(eg33) has higher levels of GST-4 
reporter than dys-1(cx18). Increased gst-4 expression leads to increased resistance to 
oxidative stress (Leiers et al., 2003), and this is entirely consistent with our oxygen 
consumption rate data for dys-1(eg33). Additionally, we also showed that dys-1(cx18) display 
temperature sensitivity in their thrashing movement. Similar movement data for dys-1(cx18) 
was reported at 25˚C (Hueston and Suprenant, 2009); thus our data are consistent with 
published data. The nonsense mutation in dys-1(cx18) corresponds to termination at AA 
2721, which is immediately before the start of spectrin repeat domain 5, which starts at AA 
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2725. The temperature sensitive nature of the movement decline in dys-1(cx18) but not dys-
1(eg33) suggests that dys-1(cx18) probably produces a partially functional protein in a 
temperature sensitive fashion. This idea of more unfolding occurring at 25˚C is consistent for 
other metastable temperature sensitive mutations in C. elegans (Ben-Zvi et al., 2009).  
 
Prednisone and melatonin improve strength in C. elegans 
 
The two pharmacological compounds that we test here, prednisone and melatonin, 
offer improvements in muscle strength and may also elucidate mechanisms behind muscle 
strength loss in muscular dystrophy. Previously, Gaud et al. (2004) reported that prednisone 
reduces the number of abnormal muscle cells in their dys-1;hlh-1 model. We demonstrate 
here that prednisone gives a functional improvement in the dys-1(eg33) animal as well. 
Although dys-1(eg33) does not exhibit major defects in the sarcomeres like in the sensitized 
models, we can still detect and treat strength declines. This is in contrast to our past work 
with integrin attachment complex mutants where both sarcomere and mitochondrial defects 
were present in animals that were detectably weaker (Etheridge et al., 2015). Our results here 
indicate that NemaFlex can detect alterations in strength in the absence of major structural 
defects in muscle, which raises the question of whether mitochondrial deficits rather than 
very minor sarcomere deficits underlie the detected loss of strength. 
While we are able to detect functional improvements under both drug treatments, the 
exact mechanism by which prednisone helps to alleviate symptoms is not known, although 
efficacy is at least in part attributed to reduction of inflammation (Parrillo and Fauci, 1979, 
Mendell et al., 1989). Another proposed mechanism is protection against mechanically 
induced muscle damage (Jacobs et al., 1996). Also, little is known about the mechanism of 
melatonin in the treatment of dystrophin-deficient muscle, although it has been demonstrated 
to reduce oxidative stress markers in erythrocytes in blood samples from humans with DMD 
(Chahbouni et al., 2011). In DMD patients treated with melatonin, several measures scoring 
oxidation and inflammation were also improved over a 9-month treatment period (Chahbouni 
et al., 2010). Functional measures were not reported for this study, but mdx mice treated with 
melatonin show decreased creatine kinase levels and improved muscle function in another 
study (Hibaoui et al., 2011). These proposed mechanisms could be studied further using the 
C. elegans DMD model that we present here. 
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dys-1(eg33) shows more clinical relevancy 
 
Given that dys-1(eg33) is weaker than the wild type and responds well to prednisone 
treatment, the standard treatment for muscular dystrophy in humans, we are convinced that 
this particular strain may currently be the most clinically relevant model of C. elegans for 
muscular dystrophy yet, especially when considering much of the muscular dystrophy work 
has been done with the genetically sensitized strain, dys-1(cx18);hlh-1. Null mutations of hlh-
1 although not inhibitory to muscle development do lead to muscle that contracts poorly and 
animals that are uncoordinated (Chen et al., 1994). The dys-1; hlh-1 mutant has been utilized 
as a way to strengthen the effects of the dys-1 mutation on muscle degeneration (Gieseler et 
al., 2000). 
While this sensitized worm may be useful for studying certain aspects of muscular 
dystrophy, its relevance to the mechanisms of muscular dystrophy in humans may be 
confounded by the presence of the additional mutation. As a result, any technique that offers 
a way to detect muscular defects or decreased function in muscle in worms with a mutation 
only in the dys-1 gene arguably offers a large advantage over these previous assays. We 
propose that future work with C. elegans muscular dystrophy models should follow two main 
thrusts: screening novel compounds and probing mechanisms using dys-1(eg33). Our 
platform is capable of identifying novel drugs or already-approved drugs used for other 
purposes that improve muscle function in dys-1(eg33). This could lead to clinical studies and 
may also help to unearth unknown mechanisms associated with dystrophin deficiency. Thus, 
answering mechanistic questions in future work is a huge priority. 
 
Conclusion 
 
NemaFlex is a promising platform for screening compounds that could potentially 
help to alleviate the loss in muscle strength associated with muscular dystrophy. This allows 
us to study muscular dystrophy mechanisms and treatments in the worm without having to 
use sensitizing mutations. Subcellular analyses looking at mitochondrial integrity also enable 
further assessment of the health of muscle in dys-1 mutants. The muscular weakness, 
thrashing deficiencies, mitochondrial fragmentation, impaired mitochondrial function, and 
drug response of dys-1(eg33) indicate a clinically relevant model for future investigations in 
the worm. Determination of muscle strength, when paired with other previously established 
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measures of worm physiology, muscle integrity, and overall health, will offer a more robust 
method for determining novel compounds for treating dystrophin-deficient worms. 
 
Materials and Methods 
 
Nematode strains and culture 
 
C. elegans strains used in this study were wild-type N2, which was provided by the 
Driscoll Lab, and dys-1(eg33) (strain BZ33) and dys-1(cx18) (strain LS292), which were 
provided by the Caenorhabditis Genetics Center (CGC). Both mutants have nonsense 
mutations in the dys-1 gene (Oh and Kim, 2013). We also used four new strains, CC96 [dys-
1(eg33) I; (jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)], CC97 [dys-1(cx18) I; 
(jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)], CC90 [dys-1(cx18) I; ccIs4251 I; 
him-8(e1489) IV.] and CC91 [dys-1(eg33) I; ccIs4251 I; him-8(e1489) IV.], generated for this 
study to evaluate sarcomere and mitochondrial network integrity in dys-1(eg33) and dys-
1(cx18), along with PJ727 [jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V] and 
CB5600 [ccIs4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp) I; him-8 (e1489) IV], which was 
also provided by the CGC. The PD55 strain was used for oxygen consumption rate 
experiments. Animals were maintained at 20˚C (unless otherwise noted) on NGM plates with 
E. coli OP50 using standard protocol. Animals for the study were age synchronized by 
transferring approximately 30 gravid adult nematodes of each strain to the various agar plates 
(with or without pharmacological treatments) and were then left to lay eggs for about 3 hours. 
Adult animals were then removed, and the agar plates with eggs were left in the 20˚C 
incubator for 3 days. Animal age is given as day of adulthood. 
 
Pharmacological treatments 
 
There were five different groups in this experiment for each of the three strains 
studied: no pharmacological intervention (control), melatonin or prednisone received during 
development only, and melatonin or prednisone received during both development and 
adulthood (Fig. 7A). NGM plates were prepared normally for the control groups. For the 
treatments, melatonin (Sigma Aldrich) and prednisone (Sigma Aldrich) were added to the 
NGM immediately after autoclaving to final concentrations of 1mM and 0.37mM, 
respectively. The prednisone concentration was chosen as 0.37mM, as this is a concentration 
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falling within the range of concentrations previously reported by Gaud et al. (2004) to reduce 
the number of damaged muscle cells in the dys-1;hlh-1 model. Similarly, a concentration of 
1mM of melatonin is within the range of melatonin concentrations previously reported to 
affect physiology, specifically the number of body bends, in wild-type C. elegans (Tanaka et 
al., 2007). Thus, drug concentrations that were selected are values known to fall within the 
range of concentrations that affect animal physiology and/or muscle health. Animals that 
continued to receive treatment after development, corresponding to introduction to the 
microfluidic device on Day 1 of adulthood, received treatments at concentrations of 0.1mM 
and 0.037mM for melatonin and prednisone, respectively. Lower concentrations were used 
due to the more direct contact with the drug in the microfluidic device as compared to the 
agar plates.  
 
Animal culture and imaging in microfluidic device 
 
When animals were ~72 hours post-hatching, they were loaded into the microfluidic 
devices along with a solution of 100 mg of E. coli mL-1 of liquid NGM (NGM without the 
agar). For animals continuing to receive the pharmacological treatment after development, 
the compound was introduced into the E. coli solution at the appropriate concentration before 
the bacteria was added to the device (Fig. 7B). On each day for the remainder of the 
experiment, the devices were washed using liquid NGM to remove progeny and debris, and a 
fresh solution of bacteria was added to the device (Fig. 7C,D). The arena of pillars and 
barriers in the outlet ports allow for the retention of adult animals and the filtering out of 
unwanted progeny, as has been previously demonstrated for C. elegans maintenance in 
microfluidic devices (Hulme et al., 2010, Wen et al., 2012, Xian et al., 2013, Wen et al., 
2014). 
After clearing the devices of progeny and debris, and before adding fresh E. coli, 
animals were imaged in the microfluidic chambers (Fig. 7C,D) for 45-second episodes at a 
rate of 5 frames per second. A Nikon Eclipse TI-E microscope with Andor Zyla sCMOS 5.5 
camera was used. Any animals that remained stationary during the first image sequence, 
although few in number, were reimaged until a movie including sufficient worm locomotion 
was obtained.  
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 Strength Measurements using NemaFlex 
 
Deflections and strength measurements were obtained using standard NemaFlex 
processing protocol, which involves automated tracking of the deflectable pillars (Fig. 7E) 
(Ghanbari et al., 2012, Johari et al., 2013, Khare et al., 2015, Qiu et al., 2015). Pillar 
deflection values extracted during image processing were converted to forces using 
Timoshenko beam deflection theory (Etheridge et al., 2015, Rahman et al., 2018). We then 
obtained animal strength from these forces by selecting for the maximal force exerted in each 
frame of the acquired image sequence and selecting for the 95th percentile value (defined as 
f95) among these maximal forces. The f95 value for an individual worm is analogous to the 
maximum voluntary force in humans, and thus defines a measure of animal muscular 
strength. Further details on the methodology and data analysis can be found in Rahman et al. 
(2018), and the custom-built software can be obtained by directly contacting our laboratory. 
Animal strengths were compared using a two-sample t-test (MATLAB, 2015b), with each 
individual animal strength value being treated as an independent sample. The only animals 
excluded from the analysis were those for which the custom-built MATLAB software failed 
to process the movie, which can result from too many air bubbles inside the microfluidic 
devices or non-uniform illumination. Animal diameters were measured using ImageJ 
software. 
 
Thrashing assay 
 
To crosscheck if worms lacking in strength also exhibit functional deficiencies in 
swimming, we used a simple thrashing assay (Gaffney et al., 2014). There were three 
different groups for each of the three strains studied (wild-type, dys-1(eg33), and dys-
1(cx18)): no pharmacological intervention (control) and melatonin (1 mM) or prednisone 
(0.37 mM) treatment through the last day of assessment. Animals were age synchronized as 
described in the strength assay and maintained on NGM agar plates throughout the 
experiment. Animals were manually picked to new plates every other day during the egg 
laying period.  
On Days 1, 3, and 5 of adulthood, movement rates of the worms were recorded using 
a thrashing assay (also referred to as swim test). Thrashing assays were carried out by picking 
a worm into 20 µl M9 buffer on a microscope slide. The number of bends in 10 seconds was 
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counted and repeated 5 times for each worm for three independent biological replicates. One 
body bend was recorded as one rightward body bend and leftward body bend. For each 
treatment, movement rates for 10 worms were measured. The differences in movement rates 
between treatment groups were analyzed using a two-sample t-test in MATLAB. The same 
method was utilized for temperature sensitivity experiments, with the exception that animals 
were cultured at 25˚C instead of 20˚C and significance was assess using a two-way ANOVA 
with Tukey’s multiple comparison test. 
 
Levamisole sensitivity assay 
 
To check for differences in levamisole sensitivity among wild type, dys-1(cx18), and dys-
1(eg33) were exposed to levamisole hydrochloride (Sigma 31742) at 100 M in M9 buffer. 
Animals were placed into 2.5 ml levamisole in 30mm petri dishes. Starting from t = 0 min, 
the numbers of paralyzed animals were scored every 10 minutes until all wild-type worms 
were paralyzed. Experiments were performed for populations of day 1 adult worms cultured 
at 20˚C or 25˚C. For worms cultured at 20˚C, two independent biological replicates were 
performed, where n=50 for each experiment (total n=100 per strain). For 25˚C, a single 
experiment was performed where n=50 per strain. 
 
Sarcomere structure  
 
 To determine if dys-1(cx18) and dys-1(eg33) worms showed defects in sarcomere 
structure the worms were stained with Rhodamine Phalloidin Stain (R415 Invitrogen). The 
phalloidin staining procedure was carried out as described by Gieseler et al. (2000).  
In addition to actin staining using phalloidin, crosses were made using PJ727 [jls01 
(myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V], which has GFP fusion proteins localized to 
the contractile apparatus, with dys-1(eg33) and dys-1(cx18). The resulting crosses were 
referred to as CC96 [dys-1(eg33) I; (jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)], 
CC97 [dys-1(cx18) I; (jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)]. Images were 
taken at days 0, 1, 2 and 3 of adulthood. All images were taken at 40x magnification using a 
Nikon Eclipse 50i microscope. 
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 Mitochondrial strains and imaging 
 
The CB5600 [ccIs4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp) I; him-8 (e1489) IV] 
strain, which has GFP fusion proteins localized to muscle mitochondria and nuclei was used 
for this study. Crosses were made between the CB5600 strain and dys-1(cx18)   and dys-
1(eg33) (strain BZ33). The resulting strains were CC90 [dys-1(cx18) I; ccIs4251 I; him-
8(e1489) IV.] and CC91 [dys-1(eg33) I; ccIs4251 I; him-8(e1489) IV.]. CB5600 were used 
for the wild-type imaging. On days 1, 3, and 5 of adulthood, animals were imaged in 20 µl 
M9 buffer on a microscope slide with a cover slip. All images were taken at 40x 
magnification using a Nikon Eclipse 50i microscope. 
 
Oxygen Consumption Rate 
 
To investigate DMD-mediated changes in mitochondrial function, oxygen consumption rate 
(OCR) measurements were performed using the Seahorse XFe24 analyzer (Agilent, Santa 
Clara, CA, USA), in line with previously described methods (Koopman et al., 2016). At day 
0 of adulthood, wild-type, dys-1(cx18) (LS292 strain), and dys-1(eg33) (BZ33 strain) animals 
were washed twice in M9 buffer and transferred into M9-filled wells (20 worms/well) in 
replicates of 5 per condition (i.e. 5 wells per strain). To generate stable OCR measurements, 5 
measurement cycles were performed for basal OCR, 9 cycles for maximal OCR following the 
addition of FCCP (10 µM final well concentration) and 5 cycles for non-mitochondrial OCR 
following the addition of sodium azide (40 nM final well concentration). A follow-up 
experiment was conducted to investigate whether prednisone treatment could rescue DMD-
mediated changes in basal OCR. To do this, basal OCR was measured, as described, in adult 
(day 1) wild-type (N2) and dys-1(eg33) animals both with and without prednisone treatment 
(20 worms/ well, 5 replicates). Prednisone-treated worms were cultured, as previously 
described, on prednisone-treated (0.37 mM) agar. OCR measurements were normalized to the 
number of worms per well. To avoid unstable OCR measurements, the final 3, 7 and 2 
measurement cycles were used for the statistical analysis of basal, maximal and non-
mitochondrial OCR, respectively.  Differences in OCR were detected with a one-way 
ANOVA with Tukey’s multiple comparison test using GraphPad Prism 6 (La Jolla, CA, 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
USA). The -level of significance was set at P < 0.05. 
 
JC-10 and MitoTracker Red Staining 
 
To assess mitochondrial membrane potential two in-vivo dyes, JC-10 (Enzo Life Sciences 
52305) and Mitotracker Red CMXRos (Invitrogen M7512), were used. Strains used for 
measuring mitochondrial membrane potential were wild type (N2), dys-1(cx18) (LS292 
strain), and dys-1(eg33) (BZ33 strain). For prednisone treated worms, animals were cultured 
as previously described on agar containing prednisone at a concentration of 0.37 mM.  On the 
first day of adulthood, 40 worms were picked into 83 M of JC-10 in freeze-dried OP50 
solution (LabTIE) for 4 hours before imaging. The worms stained with MitoTracker Red 
were imaged on the first day of adulthood and the protocol by Gaffney et al. (2014) was 
followed. Representative images are shown for each strain stained with JC-10 and 
MitoTracker Red.   
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Fig. 1. Strength measurements of muscular dystrophy model mutants. (a) Baseline 
strength of the three different strains taken at three different time points. Measurements began 
in early adulthood once animals had been transferred to the microfluidic devices. Error bars 
represent standard error of the mean. Only dys-1(eg33), not dys-1(cx18), is detectably weaker 
than the wild-type (WT) animal. This effect of dystrophin loss on animal strength is detected 
beginning on Day 3. (B) The differences in animal strength are not attributable to their 
diameters, where dys-1(eg33) animals are weaker, but not thinner, than the wild-type animals. 
[N for Day 1, 3, 5. WT: N=27, 23, 22. dys-1(cx18): N=29, 24, 22. dys-1(eg33): N=28, 21, 18. 
Single replicate analyzed with a two-sample t-test.] 
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Fig. 2. Effect of pharmacological interventions on nematode strength. The strengths for 
three different strains, each with a control and four treatments, are shown here. Each strain 
was treated with melatonin and prednisone during development alone (M1, P1) or during 
development and adulthood both (M2, P2); the “C” label designates the control animals 
which received no treatment. With the exception of wild-type animals undergoing 
development-only prednisone treatment, the (A) wild-type and (B) dys-1(cx18) have no 
changes in strength in response to treatment. (C) In contrast, all dys-1(eg33) animals improve 
their strength under any of the four treatments beginning on Day 3. Worm diameters do not 
fluctuate much for WT (D), dys-1(cx18) (E), or dys-1(eg33) (F) under the various treatments. 
In the case of dys-1(eg33), the diameter is not influenced at all by any treatments on Days 3 
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and 5, the time points at which strength improves drastically under treatment. These data 
indicate strength improvements are not due to changes in animal size. All error bars represent 
standard error of the mean. [N for Day 1, 3, 5. WT- M1: N=27, 26, 25; M2: N=26, 25, 26; 
P1: N=26, 24, 23; P2: N= 27, 24, 22. dys-1(cx18)- M1: N=29, 27, 25; M2: N=30, 24, 24; P1: 
N=28, 28, 21; P2: N=28, 28, 26. dys-1(eg33)- M1: N=27, 25, 23; M2: N=29, 25, 25; P1: 
N=29, 26, 23; P2: N=27, 25, 26. Single replicate analyzed with a two-sample t-test.] 
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Fig. 3. Swimming dystrophin mutants have lower thrashing rates than wild-type, and 
both dys-1(cx18) and dys-1(eg33) respond positively to treatments. (A) Both dys-1(cx18) 
and dys-1(eg33) have lower thrashing rates than wild-type across all ages. (B) WT, (C) dys-
1(cx18), and (D) dys-1(eg33) have varying responses to drug treatments. The most prominent 
response is that of dys-1(eg33), which improves its thrashing rate drastically under both 
treatments at all time points. All error bars represent standard error of the mean. For all 
strains and treatments at each time point, N=10 with 5 replicates for each worm with 3 
independent biological replicates for a total of 150 data points per bar; results were analyzed 
with a two-sample t-test. 
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Fig. 4. dys-1(cx18) shows a temperature sensitive phenotype and dys-1(cx18) and dys-
1(eg33) are levamisole resistant. (A) Day 1 adult dys-1(cx18) animals have lower thrashing 
rates when cultured at 25˚C compared to at 20˚C, while dys-1(eg33) is not affected by higher 
culture temperatures. Thus, dys-1(cx18) appears to be temperature sensitive. For all strains 
and treatments at each time point, N=10 with 5 replicates for each worm with 3 independent 
biological replicates for a total of 150 data points per bar. Significances were analyzed using 
a two-way ANOVA with Tukey’s multiple comparison test. (B,C) dys-1(cx18) has a mild 
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levamisole resistance compared to wild-type, while dys-1(eg33) has a high resistance, both at 
20˚C and 25˚C. At 20˚C, n=50 for two independent biological replicates (total n=100 per 
strain) and for 25˚C, n=50 per strain. ***/** indicates significant difference in response to 
levamisole vs. other strains tested (p<0.001/p<0.01 with 2-way repeated measures ANOVA). 
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Fig. 5. There are no differences in sarcomere structure between dys-1 and wild-type 
worms; however, mitochondrial network defects are apparent ,and pharmacological 
intervention prevents degradation from occurring. A) Representative images of wild-type, 
dys-1(cx18), and dys-1(eg33) worms stained with Phalloidin on day 1 of adulthood. B) 
Representative images of PJ727, CC97 (dys-1(cx18)) and CC96 (dys-1(eg33)) worms at day 
3 of adulthood. Sarcomere defects are not apparent in either dys-1 mutant. Scale bar 
represents 25 μm. (C) CB5600 (wild-type with GFP-tagged mitochondria) animals have 
tubular mitochondrial network appearance, which is also maintained in animals treated with 
prednisone and melatonin. (D) CC90 animals (GFP-tagged mitochondria in dys-1(cx18)) 
exhibit minor fragmentation in the mitochondrial network, which is remedied by prednisone 
but not melatonin. (E) CC91 animals (GFP-tagged mitochondria in dys-1(eg33)) have 
noticeably fragmented mitochondrial networks. Animals treated with prednisone do not 
display this phenotype and instead have relatively wild-type-like appearance in the 
mitochondrial network. Animals treated with melatonin have slightly improved mitochondrial 
network but are not improved to wild-type levels. Scale bar represents 25 μm, and the 
enlarged regions are an additional 1.7× magnification. 
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Fig. 6. Mitochondrial dysfunction is also a phenotype of dys-1(eg33). (A) JC-10 and 
MitoTracker Red stained mitochondria show moderate depolarization of the mitochondrial 
membrane in dys-1(cx18) and severe depolarization in dys-1(eg33). This defect is not 
remedied by treatment with prednisone in dys-1(eg33). The scale bar represents 30 µm. (B) 
Compared to control groups and dys-1(cx18), dys-1(eg33) has an abnormally high basal 
oxygen consumption rate (OCR), while maximal respiratory capacity was not affected. 
Significances were assessed using a one-way ANOVA and Bonferroni multiple corrections. 
(C) Treatment with prednisone restores basal OCR to wild-type levels in dys-1(eg33) 
animals. Significances were assessed using a one-way ANOVA with Tukey’s multiple 
comparison test. All OCR data is based on 20 worms per well with 5 wells per 
strain/condition. 
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Fig. 7. Experimental protocol for testing efficacy of pharmacological compounds and 
the microfluidic platform used from the beginning of adulthood. (A) A summary of the 
different treatments and associated abbreviation used to describe each treatment. (B) Animals 
start out on agar for the first 3 days when development is occurring, and all animals except 
the control group of each strain receive a pharmacological treatment (purple). On the first day 
of adulthood, all animals are transferred to the devices where they are fed and imaged over 
the next few days; animals receiving lifelong treatment continue to receive compounds in the 
microfluidic device (shown in purple). (C) A view of the 30-chamber microfluidic chip used 
to house the nematodes from days 1-5 of adulthood. The device is bonded on a standard 
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75x50mm glass slide. (D) An image of a microfluidic chamber used to house a single worm. 
The deflectable pillars enable force measurement. Scale bar represents 300 μm. (E) A close-
up view of some of the pillars being tracked for deflection via the NemaFlex image 
processing software. Pillars currently in contact with the worm are shown in red, while pillars 
that are deflected in a different frame of the image sequence are shown in blue. Scale bar 
represents 100 μm. 
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